{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:26:08Z","timestamp":1761920768813,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.msard.2020.102310","type":"journal-article","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T20:14:05Z","timestamp":1592684045000},"page":"102310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Decision-making on management of ms and nmosd patients during the COVID-19 pandemic: A latin american survey"],"prefix":"10.1016","volume":"44","author":[{"given":"Alonso","family":"Ricardo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar","family":"Carnero Contentti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silva Berenice","family":"Anabel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00f3pez Pablo","family":"Adrian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garcea","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamuy","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rivera","family":"V\u00edctor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gracia","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rojas Juan","family":"Ignacio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102310_bib0001","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3988\/jcn.2018.14.4.487","article-title":"Changes in the Multiple Sclerosis Treatment Paradigm. What Do We Do Now and What Were We Doing Before?","volume":"14","author":"Alonso","year":"2018","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.msard.2020.102310_bib0002","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1212\/NXI.0000000000000360","article-title":"Both cladribine and alemtuzumab may effect MS via B-cell depletion","volume":"4","author":"Baker","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.msard.2020.102310_bib0003","article-title":"The ocrelizumab phase II extension trial suggests the potential to improve the risk:benefit balance in multiple sclerosis","volume":"2020","author":"Baker","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.msard.2020.102310_bib0004","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/ana.23758","article-title":"Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta","volume":"73","author":"Bermel","year":"2013","journal-title":"Ann Neurol."},{"key":"10.1016\/j.msard.2020.102310_bib0005","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med."},{"key":"10.1016\/j.msard.2020.102310_bib0006","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000009507","article-title":"Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic","author":"Brownlee","year":"2020","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2020.102310_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102097","article-title":"Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: a new challenge","volume":"41","author":"Carnero Contentti","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"10.1016\/j.msard.2020.102310_bib0008","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ene.13186","article-title":"Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder","volume":"24","author":"Chen","year":"2017","journal-title":"Eur J Neurol."},{"key":"10.1016\/j.msard.2020.102310_bib0009","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/14740338.2019.1658741","article-title":"An update on the safety of treating relapsing-remitting multiple sclerosis","volume":"18","author":"Chisari","year":"2019","journal-title":"Expert Opin Drug Saf."},{"key":"10.1016\/j.msard.2020.102310_bib0010","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40263-013-0042-5","article-title":"Switching therapies in multiple sclerosis","volume":"27","author":"Coyle","year":"2013","journal-title":"CNS Drugs."},{"key":"10.1016\/j.msard.2020.102310_bib0011","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.msard.2020.102310_bib0012","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jns.2018.01.004","article-title":"Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients","volume":"385","author":"Cristiano","year":"2018","journal-title":"J Neurol Sci."},{"key":"10.1016\/j.msard.2020.102310_bib0013","first-page":"157","article-title":"WHO Declares COVID-19 a Pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta bio-medica: Atenei Parmensis."},{"key":"10.1016\/j.msard.2020.102310_bib0014","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.msard.2019.01.039","article-title":"Highly active multiple sclerosis: an update","volume":"30","author":"Diaz","year":"2019","journal-title":"Mult Scler Relat Disord."},{"key":"10.1016\/j.msard.2020.102310_bib0015","unstructured":"European Medicine Agency. Gilenya, INN Fingolimod. 2020. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/gilenya-epar-product-information_en.pdf2020."},{"key":"10.1016\/j.msard.2020.102310_bib0016","unstructured":"Multiple Sclerosis Intenational Federation. 2020. The coronavirus and MS \u2013 global advice. In: Federation MSI, (ed.). https:\/\/www.msif.org\/news\/2020\/02\/10\/the-coronavirus-and-ms-what-you-need-to-know\/2020."},{"key":"10.1016\/j.msard.2020.102310_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102073","article-title":"The COVID-19 pandemic and the use of MS disease-modifying therapies","volume":"39","author":"Giovannoni","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"10.1016\/j.msard.2020.102310_bib0018","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jamaneurol.2014.4147","article-title":"Comparison of switch to fingolimod or interferon beta\/glatiramer acetate in active multiple sclerosis","volume":"72","author":"He","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2020.102310_bib0019","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.msard.2020.102310_bib0020","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.msard.2019.08.009","article-title":"Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: a systematic review and network meta-analysis","volume":"35","author":"Huang","year":"2019","journal-title":"Mult Scler Relat Disord."},{"key":"10.1016\/j.msard.2020.102310_bib0021","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/cei.12261","article-title":"Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab","volume":"176","author":"Koudriavtseva","year":"2014","journal-title":"Clin Exp Immunol."},{"key":"10.1016\/j.msard.2020.102310_bib0022","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/qjmed\/hct046","article-title":"Lymphopenia as risk factor for development of severe infections in patients with systemic lupus erythematosus: a case-control study","volume":"106","author":"Merayo-Chalico","year":"2013","journal-title":"QJM."},{"key":"10.1016\/j.msard.2020.102310_bib0023","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/qjmed\/hci155","article-title":"Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus","volume":"99","author":"Ng","year":"2006","journal-title":"QJM."},{"key":"10.1016\/j.msard.2020.102310_bib0024","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.msard.2020.102310_bib0025","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/1352458515594042","article-title":"Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients","volume":"22","author":"Radaelli","year":"2016","journal-title":"Mult Scler."},{"key":"10.1016\/j.msard.2020.102310_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101613","article-title":"COVID-19 in Latin America: the implications of the first confirmed case in Brazil","author":"Rodriguez-Morales","year":"2020","journal-title":"Travel Med Infect Dis."},{"key":"10.1016\/j.msard.2020.102310_bib0027","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41582-019-0170-8","article-title":"Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis","volume":"15","author":"Rotstein","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.msard.2020.102310_bib0028","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008243","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","author":"Ryerson","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102310_bib0029","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2020.102310_bib0030","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-018-8812-0","article-title":"Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation","volume":"265","author":"Tallantyre","year":"2018","journal-title":"J Neurol."},{"key":"10.1016\/j.msard.2020.102310_bib0031","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/ane.12667","article-title":"Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society","volume":"135","author":"Vagberg","year":"2017","journal-title":"Acta Neurol Scand."},{"key":"10.1016\/j.msard.2020.102310_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002685","article-title":"Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study","volume":"15","author":"Warny","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.msard.2020.102310_bib0033","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00415-020-09822-3","article-title":"Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19\/SARS-CoV-2","volume":"267","author":"Willis","year":"2020","journal-title":"J Neurol"},{"key":"10.1016\/j.msard.2020.102310_bib0034","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.msard.2020.102310_bib0035","first-page":"91","article-title":"Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and meta-analysis","volume":"94","author":"Yang","year":"2020","journal-title":"International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases."},{"key":"10.1016\/j.msard.2020.102310_bib0036","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jns.2017.12.034","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder","volume":"385","author":"Yang","year":"2018","journal-title":"J Neurol Sci."},{"key":"10.1016\/j.msard.2020.102310_bib0037","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820303862?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820303862?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:51:27Z","timestamp":1761900687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820303862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":37,"alternative-id":["S2211034820303862"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102310","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decision-making on management of ms and nmosd patients during the COVID-19 pandemic: A latin american survey","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102310","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102310"}}